S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat Leukemias in Japan and Nine Other Asian Countries (2014/12/23)|
|ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries|
|ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia|
|ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years|
|ARIAD Reports Third Quarter 2014 Financial Results and Development Progress|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial|
|ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia|
|ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial|
|ARIAD Announces Phase 2 Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015|
|ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe|
Click above to view more mutual fund data and stats for aria - ARIAD Pharmaceuticals Inc.